Literature DB >> 33866447

Anthelmintic resistance of gastrointestinal nematodes in sheep grazing in irrigated and dry areas in the semiarid region of northeastern Brazil.

Lauricia S Nascimento1, Anna M C F Evaristo1, Glauber M B Oliveira1,2, Matheus S Ferreira1, Déborah L R Silva1, Sergio S Azevedo3, Sandra M Yamamoto1, Márcia M Araújo1, Mauricio C Horta4.   

Abstract

This study aimed to determine the AR of gastrointestinal nematodes (GIN) to commercial drugs in sheep flocks naturally infected, grazing in irrigated (IA) and dry (DA) areas of the semiarid region in northeastern Brazil. Fecal egg count reduction tests (FECRT) were performed at 10 farms. From each flock, 36 adult sheep were selected and divided into five groups (G1 (0.08% ivermectin), G2 (10% albendazole), G3 (5% levamisole), G4 (1% moxidectin), G5 (10% closantel) and one control group, G6). All the commercial drugs were found to reduce the number of eggs per gram of feces (EPG). Resistance to ivermectin (37.1%), albendazole (52.1%), and levamisole (52.0%) was detected at all the farms, but nematodes proved to be susceptible to moxidectin (87.9%) and closantel (83.9%). The overall average efficacy of the commercial drugs was significantly higher (P < 0.05) in DA (49.2%), where moxidectin (90.4%) showed high effectiveness. The presence of the parasite Haemonchus contortus predominated at all the farms. The variables irrigated area (P = 0.002), intensive breeding (P = 0.018), uncovered enclosures (P = 0.05), cultivated (P = 0.043) and native/cultivated (P = 0.007) pastures, and rotational grazing (P = 0.013) were significantly associated with GIN infection; irrigated area (P = 0.009), semi-intensive breeding (P = 0.05), rotational grazing (P = 0.045), cultivated (P = 0.021) and native/cultivated (P = 0.04) pastures, and estimated weighing of animals (P = 0.002) were significantly associated with AR. Therefore, improved management practices and strategic deworming must be implemented to prevent the development of AR.

Entities:  

Keywords:  Effectiveness; Gastrointestinal parasites; Multidrug resistance; Small ruminants

Mesh:

Substances:

Year:  2021        PMID: 33866447     DOI: 10.1007/s11250-021-02647-w

Source DB:  PubMed          Journal:  Trop Anim Health Prod        ISSN: 0049-4747            Impact factor:   1.559


  2 in total

Review 1.  Refugia and anthelmintic resistance: Concepts and challenges.

Authors:  Jane E Hodgkinson; Ray M Kaplan; Fiona Kenyon; Eric R Morgan; Andrew W Park; Steve Paterson; Simon A Babayan; Nicola J Beesley; Collette Britton; Umer Chaudhry; Stephen R Doyle; Vanessa O Ezenwa; Andy Fenton; Sue B Howell; Roz Laing; Barbara K Mable; Louise Matthews; Jennifer McIntyre; Catherine E Milne; Thomas A Morrison; Jamie C Prentice; Neil D Sargison; Diana J L Williams; Adrian J Wolstenholme; Eileen Devaney
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-05-17       Impact factor: 4.077

Review 2.  Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance.

Authors:  Roger K Prichard; Timothy G Geary
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-06-15       Impact factor: 4.077

  2 in total
  2 in total

1.  An Artemisia cina n-hexane extract reduces the Haemonchus contortus and Teladorsagia circumcincta fecal egg count in naturally infected periparturient goats.

Authors:  Rosa Isabel Higuera-Piedrahita; Mariana Dolores-Hernández; Héctor Alejandro de la-Cruz-Cruz; Héctor Mario Andrade-Montemayor; Alejandro Zamilpa; Raquel López-Arellano; Roberto González-Garduño; Jorge Alfredo Cuéllar-Ordaz; Pedro Mendoza-de-Gives; Ma Eugenia López-Arellano
Journal:  Trop Anim Health Prod       Date:  2022-02-09       Impact factor: 1.559

2.  Poloxamer 407/188 Binary Thermosensitive Gel as a Moxidectin Delivery System: In Vitro Release and In Vivo Evaluation.

Authors:  Xiangchun Ruan; Jidong Hu; Lianshou Lu; Youwei Wang; Chunlian Tang; Faquan Liu; Xiuge Gao; Li Zhang; Hao Wu; Xianhui Huang; Qing Wei
Journal:  Molecules       Date:  2022-05-10       Impact factor: 4.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.